RESUMEN
A strong scientific rationale exists for conducting clinical pharmacology studies in target populations because local factors such as genetics, environment, comorbidities, and diet can affect variability in drug responses. However, clinical pharmacology studies are not widely conducted in sub-Saharan Africa, in part due to limitations in technical expertise and infrastructure. Since 2012, a novel public-private partnership model involving research institutions and a pharmaceutical company has been applied to developing increased capability for clinical pharmacology research in multiple African countries.
Asunto(s)
Investigación Biomédica/tendencias , Farmacología Clínica/tendencias , Asociación entre el Sector Público-Privado/tendencias , África del Sur del Sahara/epidemiología , Investigación Biomédica/métodos , Ensayos Clínicos como Asunto/métodos , Humanos , Cooperación Internacional , Farmacogenética/métodos , Farmacogenética/tendencias , Farmacología Clínica/métodosRESUMEN
Zimbabwe (population 11,365,000) introduced nationwide one-dose measles vaccination in 1981. This strategy reached 70%-80% of infants <1 year of age over the next two decades; in 1998, a nationwide supplemental immunization activity (SIA) targeting all children aged 9 months to 14 years achieved 93% coverage. Surveillance data were examined to determine the impact of these strategies. During 1985-1997, there were 8529-49,812 measles cases annually. After the SIA, laboratory confirmation of the first 5 outbreak cases and all sporadic cases was required. In 1999 and 2000, 1343 (88%) of 1534 suspected cases had adequate specimens submitted and 28 (2%) were measles IgM positive. In 2001, of 529 suspected cases, 513 (97%) had adequate specimens and only 7 (1%) were measles IgM positive. These data suggest that indigenous measles transmission in Zimbabwe has been interrupted and that high prevalence of human immunodeficiency virus seropositivity does not hinder vaccination-induced measles control. High vaccination coverage obtained through the routine health care system supplemented by periodic follow-up SIAs will be required to maintain low transmission levels.
Asunto(s)
Brotes de Enfermedades , Vacunación Masiva/métodos , Vacuna Antisarampión/administración & dosificación , Sarampión/prevención & control , Adolescente , Anticuerpos Antivirales/sangre , Niño , Preescolar , Humanos , Incidencia , Lactante , Vacunación Masiva/normas , Sarampión/epidemiología , Vigilancia de la Población , Zimbabwe/epidemiologíaRESUMEN
Neonatal tetanus (NT) elimination, < 1 case per 1,000 live births (LB), was assessed at district level in Zimbabwe using a combined lot quality assurance-cluster sampling survey (LQA-CS). Three of the highest risk districts were selected. NT was considered eliminated if fewer than a specified number of NT deaths (proxy for NT cases) were found in the sample determined using operating characteristic curves and tables. TT2 + vaccine coverage was measured in mothers who gave birth 1-13 months before the survey and women aged 15-49 years. NT was considered as eliminated, TT2+ coverage was 78% (95% CI 71-82%) in women aged 15-49 and 83% (95% CI 76-89%) in mothers. The survey cost 30,000 US dollars excluding costs of consultants. NT incidence was below the elimination threshold (< 1/1,000 LB) in the surveyed districts and probably in all districts. LQA-CS is a practical, relatively cost effective field method which can be applied in an African setting to assess NT elimination status.
